·病例报告·

　　　【摘要】 患者女，69岁，高血压病病史10年，既往无糖尿病病史，于2003年4月开始口服吲达帕胺药物治疗，服药前血糖4.2 mmol/L。2012年12月患者体检测FPG 8.5 mmol/L，后连续两日复查FPG分别为7.2 mmol/L、7.9 mmol/L，诊断为糖尿病。未行饮食及降糖药物治疗，停服吲达帕胺1周后复查2次FPG分别为5.4 mmol/L、5.3 mmol/L，1月后复查FPG为4.9 mmol/L。提示长期口服吲达帕胺可诱发糖尿病，且吲达帕胺对患者的糖代谢损害是可逆的。

　　【关键词】 糖尿病;吲达帕胺

　　【Summary】 A 69 years old female patient with a history of hypertension for 10 years without history of diabetes began a long-term oral indapamide therapy from April of 2003 to 2013.His fasting blood glucose before the therapy was 4.2 mmol/L. In December of 2012, his fasting blood glucose was 8.5 mmol/L. We re-examined fasting blood glucose were 7.2 mmol/L and 7.9 mmol/L in the consecutive days. The patient was diagnosed as diabetes. One week after stoping the indapamide and without diet and hypoglycemic drug therapies, the fasting blood glucose was 5.4 mmol/L, 5.3 mmol/L. And it was 4.9 mmol/L after one more month. The above suggests that long-term oral indapamide may induce hyperglycemia and even diabetes. And the influence of indapamide on the glucose metabolism is reversible.

　　【Key words】 Diabetes mellitus; Indapamide